-
Uncategorized3 weeks agoNovel regulatory science considerations in osteosarcoma: the imperative for regulatory flexibility to meet critical unmet patient and clinical needs
Introduction Rare diseases, as classified by the FDA and EMA, are conditions that affect fewer than 200,00 people in the US1 or fewer than five in...
-
Uncategorized3 weeks ago
Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors
Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it picked up from Verve Therapeutics, with the candidate now...
-
Uncategorized3 weeks agoBioMarin notches win in study that could expand use of top-selling medicine
The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid increased competition. Read More
-
Uncategorized3 weeks ago
Roche licensing pact clears generic drugmakers to manufacture antiviral flu drug
Roche licensing pact clears generic drugmakers to manufacture antiviral flu drug
-
Uncategorized3 weeks ago
BioMarin to seek further approval of Voxzogo in form of short stature
BioMarin Pharmaceutical will seek expanded approval for its bone growth-stimulating drug Voxzogo after the shot improved growth speed in children with a form of short stature,...
-
Uncategorized3 weeks ago
Incyte signs AI deals with Genesis Molecular AI, Edison Scientific
Over a 35-year history, Incyte has grown into a $19 billion biopharma company. The Delaware-based drugmaker is now turning to AI to power through the coming...
-
Uncategorized3 weeks agoLive: Senate committee questions NIH director on 2027 budget
National Institutes of Health Director Jay Bhattacharya is appearing in front of the Senate Appropriations Committee Wednesday, starting at 10 a.m. ET, to discuss President Trump’s...
-
Uncategorized3 weeks ago
BMS eyes new campus in Texas; Novartis looks to evict tenant at Slovenian campus
Plus, news about Gilead and West Pharma: 🏭Bristol Myers Squibb looks to Texas: The drugmaker is considering building a new pharma campus in Generation Park Management...
-
Uncategorized3 weeks ago
Lilly’s triple agonist shows bariatric surgery–like weight loss results
Lilly met analysts’ sky-high expectations with 28.3% weight loss over 80 weeks for the triple hormone receptor agonist retatrutide in a highly anticipated readout on Thursday.
-
Uncategorized3 weeks agoHow Florida hospitals won big in Medicaid funds (just in time)
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning and happy Thursday. Later this morning,...
STAT+: At hospital finance conference, a call to end the friction that’s keeping costs high
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks
